Sold as Alkeran. Every FDA application for this active ingredient: 1 branded and 1 generic.
As of Nov 13, 2026, FDA lists 2 applications for Melphalan (sold as Alkeran), first approved Jan 17, 1964, with 0 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2024 | Change | Beneficiaries |
|---|---|---|---|---|
| Alkeran | Part B | $242K | -12% | 235 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number. Drugs@FDA
Apotex